A risk scoring system to predict coronary stent thrombosis

References

• Buchanan GL, Basavarajaiah S, Chieffo A. Stent thrombosis: incidence, predictors and new technologies. Thrombosis 2012;2012:956962
   PubMedGoogle Scholar
• Centemero MP, Stadler JR. Stent thrombosis: an overview. Expert Rev Cardiovasc Ther 2012;10:599-615
   PubMedGoogle Scholar
• Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010;56:1357-65
   PubMed Web of Science ®Google Scholar
• Van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009;119:828-34
   PubMed Web of Science ®Google Scholar
• D’Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013;167:575-84
   PubMed Web of Science ®Google Scholar
• Motovska Z, Knot J, Widimsky P. Stent thrombosis – risk assessment and prevention. Cardiovasc Ther 2010;28:e92-100
   PubMed Web of Science ®Google Scholar
• Lemesle G, Delhaye C, Bonello L, et al. Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Arch Cardiovasc Dis 2008;101:769-77
   PubMed Web of Science ®Google Scholar
• Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2012;5:1043-51
   PubMed Web of Science ®Google Scholar
• Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011;306:1765-74
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ. Incorporating Bayesian ideas into health-care evaluation. Stat Sci 2004;19:156-74
   Web of Science ®Google Scholar
• FDA clinical overview for panel packet. DES thrombosis panel, 7–8 December 2006. US Food and Drug Administration. Silver Spring, MD: US FDA, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4253b1_01.pdf [Last accessed 30 May 2014]
   Google Scholar
• Ibrahim JG, Chen MH. Power prior distributions for regression models. Stat Sci 2000;15:46-60
   Web of Science ®Google Scholar
• Thangaratinam S, Redman C. The Delphi technique. The Obstetrician & Gynaecologist 2005;7:120-5
   Google Scholar
• Hosmer DW, Lemeshow S. Goodness of fit tests for the multiple logistic regression model. Commun Stat Theory Methods 1980;10:1043-69
   Web of Science ®Google Scholar
• de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998;19:1214-23
   PubMed Web of Science ®Google Scholar
• Tsai ML, Chen CC, Yang CH, et al. Review: the outcomes of different vessel diameter in patients receiving coronary artery stenting. Int J Cardiol 2016;224:317-22
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66
   PubMed Web of Science ®Google Scholar
• Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015;65:1298-310
   PubMed Web of Science ®Google Scholar
• Feres F, Costa RA, Abizaid A, et al.; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-22
   PubMed Web of Science ®Google Scholar
• Watson J. Men and health: report of a Delphi study to scope themes for evidence-based reviews. London: NHS Health Development Agency, April 2004. Available at: http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=82F67D87F033F26099EA43C34F204982?doi=10.1.1.219.1799&rep=rep1&type=pdf [Last accessed 30 May 2014]
   Google Scholar
• Naidu SS, Krucoff MW, Rutledge DR, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv 2012;5:626-35
   PubMed Web of Science ®Google Scholar
• Heestermans AA, van Werkum JW, Zwart B, et al. Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. J Thromb Haemost 2010;8:2385-93
   PubMed Web of Science ®Google Scholar
• Park KW, Hwang SJ, Kwon DA, et al.; Korea Stent Thrombosis Investigators. Characteristics and predictors of drug-eluting stent thrombosis: results from the multicentre ‘Korea Stent Thrombosis (KoST)’ registry. Circ J 2011;75:1626-32
   PubMed Web of Science ®Google Scholar
• Dangas GD, Claessen BE, Mehran R, et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv 2012;5:1097-105
   PubMed Web of Science ®Google Scholar
• Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009;119:1873-82
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55:2556-66
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800
   PubMed Web of Science ®Google Scholar
• Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252-63
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-8
   PubMed Web of Science ®Google Scholar
• Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086-97
   PubMed Web of Science ®Google Scholar
• Eagle KA, Lim MJ, Dabbous OH, et al.; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33
   PubMed Web of Science ®Google Scholar
• Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42
   PubMed Web of Science ®Google Scholar
• Linstone HA. The Delphi technique. In: Fowles RB, editor. Handbook of Futures Research. Westport, CT: Greenwood, 1978:271-300
   Google Scholar